Patents by Inventor Andrew Ihor Korytko

Andrew Ihor Korytko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSION PROTEINS
    Publication number: 20220211818
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: January 18, 2022
    Publication date: July 7, 2022
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Fusion proteins and methods of use
    Patent number: 11253574
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: February 22, 2022
    Assignee: Eli Lilly and Company
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Anti-RANKL antibodies and uses thereof
    Patent number: 10913799
    Abstract: Antibodies and methods of using these antibodies are provided which bind human and mouse receptor activator of nuclear factor kappa-B ligand, said antibodies are useful as agents for treating conditions associated with bone-related disorders or skeletal abnormalities caused by cancer.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: February 9, 2021
    Assignee: Eli Lilly and Company
    Inventors: Andrew Ihor Korytko, Victor H Obungu
  • FUSION PROTEINS
    Publication number: 20200390865
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: June 5, 2020
    Publication date: December 17, 2020
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Fusion proteins
    Patent number: 10709766
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: July 14, 2020
    Assignee: Eli Lilly and Company
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • ANTI-RANKL ANTIBODIES AND USES THEREOF
    Publication number: 20190284289
    Abstract: Antibodies and methods of using these antibodies are provided which bind human and mouse receptor activator of nuclear factor kappa-B ligand, said antibodies are useful as agents for treating conditions associated with bone-related disorders or skeletal abnormalities caused by cancer.
    Type: Application
    Filed: October 20, 2017
    Publication date: September 19, 2019
    Inventors: Andrew Ihor Korytko, Victor H Obungu
  • Blood glucose lowering compound
    Patent number: 10035839
    Abstract: The present invention relates to the field of medicine and the treatment of diabetes or hyperglycemia within that field. More particularly, the invention relates to a compound that lowers blood glucose, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound. The compound claimed herein comprises an A chain and a B chain, wherein the amino acid sequence of the A chain is SEQ ID NO: 1 and the amino acid sequence of the B chain is SEQ ID NO: 2.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: July 31, 2018
    Assignees: Eli Lilly and Company, Amunix Operating Inc.
    Inventors: David Bruce Baldwin, John Michael Beals, Andrew Ihor Korytko, Bryant Rhodius McLaughlin, Volker Schellenberger
  • FUSION PROTEINS
    Publication number: 20180177851
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: November 22, 2017
    Publication date: June 28, 2018
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Fusion proteins
    Patent number: 9855318
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: January 2, 2018
    Assignee: Eli Lilly and Company
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • BLOOD GLUCOSE LOWERING COMPOUND
    Publication number: 20170240614
    Abstract: The present invention relates to the field of medicine and the treatment of diabetes or hyperglycemia within that field. More particularly, the invention relates to a compound that lowers blood glucose, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 24, 2017
    Inventors: David Bruce BALDWIN, John Michael BEALS, Andrew Ihor KORYTKO, Bryant Rhodius McLAUGHLIN, Volker SCHELLENBERGER
  • FUSION PROTEINS
    Publication number: 20160324932
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: April 28, 2016
    Publication date: November 10, 2016
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Anti-sclerostin antibodies
    Patent number: 8257704
    Abstract: Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: September 4, 2012
    Assignee: Eli Lilly and Company
    Inventors: Andrew Ihor Korytko, David Matthew Marquis, Eric Michael Smith, Barbara Anne Swanson
  • Anti-myostatin antibodies
    Patent number: 8066995
    Abstract: Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bond density, or for the treatment of various disorders in mammalian and avian species, X17251.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: November 29, 2011
    Assignee: Eli Lilly and Company
    Inventors: Julian Davies, Bryan Edward Jones, Andrew Ihor Korytko, Pamela Jean Mitchell, Rosamund Carol Smith, Linda O'Bryan (Nee Tobias), Rong Wang
  • ANTI-SCLEROSTIN ANTIBODIES
    Publication number: 20110250205
    Abstract: Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.
    Type: Application
    Filed: June 21, 2011
    Publication date: October 13, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Andrew Ihor KORYTKO, David Matthew MARQUIS, Eric Michael SMITH, Barbara Anne SWANSON
  • GLUCAGON RECEPTOR ANTAGONISTS
    Publication number: 20110212092
    Abstract: The present invention relates to glucagon receptor polypeptide antagonists which inhibit the binding of the hormone glucagon to its receptor. More particularly, the present invention relates to high affinity glucagon receptor antibodies or Fab fragments thereof that inhibit binding of glucagon to its receptor and their use in the treatment or prevention of type 2 diabetes (NIDDM) and related disorders in mammalian species.
    Type: Application
    Filed: May 16, 2011
    Publication date: September 1, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Andrew Ihor KORYTKO, Rohn Lee MILLICAN, JR.
  • Methods of treatment comprising administering an anti-sclerostin antibody
    Patent number: 7988970
    Abstract: Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.
    Type: Grant
    Filed: May 13, 2010
    Date of Patent: August 2, 2011
    Assignee: Eli Lilly and Company
    Inventors: Andrew Ihor Korytko, David Matthew Marquis, Eric Michael Smith, Barbara Anne Swanson
  • Glucagon receptor antagonists
    Patent number: 7968686
    Abstract: The present invention relates to glucagon receptor polypeptide antagonists which inhibit the binding of the hormone glucagon to its receptor. More particularly, the present invention relates to high affinity glucagon receptor antibodies or Fab fragments thereof that inhibit binding of glucagon to its receptor and their use in the treatment or prevention of type 2 diabetes (NIDDM) and related disorders in mammalian species.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: June 28, 2011
    Assignee: Eli Lilly and Company
    Inventors: Andrew Ihor Korytko, Rohn Lee Millican, Jr.
  • Anti-Sclerostin Antibodies
    Publication number: 20100221263
    Abstract: Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.
    Type: Application
    Filed: May 13, 2010
    Publication date: September 2, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Andrew Ihor Korytko, David Matthew Marquis, Eric Michael Smith, Barbara Anne Swanson
  • Anti-sclerostin antibodies
    Patent number: 7744874
    Abstract: Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: June 29, 2010
    Assignee: Eli Lilly and Company
    Inventors: Andrew Ihor Korytko, David Matthew Marquis, Eric Michael Smith, Barbara Anne Swanson
  • Anti-myostatin antibodies
    Patent number: 7745583
    Abstract: A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing hone density, or for the treatment of various disorders in mammalian and avian species.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: June 29, 2010
    Assignee: Eli Lilly and Company
    Inventors: Bomie Han, Andrew Ihor Korytko, Pamela Jean Mitchell, Rosamund Carol Smith, Linda O'Bryan (Nee Tobias), Rong Wang